losartan has been researched along with Cystic Fibrosis in 4 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 3 (75.00) | 2.80 |
Authors | Studies |
---|---|
Kim, MD | 2 |
Bengtson, CD | 1 |
Yoshida, M | 2 |
Niloy, AJ | 1 |
Dennis, JS | 2 |
Baumlin, N | 2 |
Salathe, M | 2 |
Polineni, D | 1 |
Salathe, SF | 1 |
David, JK | 1 |
Peloquin, CA | 1 |
Wanner, A | 1 |
Sailland, J | 1 |
Whitney, P | 1 |
Horrigan, FT | 1 |
Sabater, JR | 1 |
Abraham, WM | 1 |
Bonfield, TL | 1 |
Chan, HC | 1 |
Law, SH | 1 |
Leung, PS | 1 |
Fu, LX | 1 |
Wong, PY | 1 |
4 other studies available for losartan and Cystic Fibrosis
Article | Year |
---|---|
Losartan ameliorates TGF-β1-induced CFTR dysfunction and improves correction by cystic fibrosis modulator therapies.
Topics: Benzodioxoles; Cyclooxygenase 2; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulato | 2022 |
Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Bronchi; Cells, Cultured; Cystic Fibrosis; Disease | 2020 |
Preclinical Modeling for Therapeutic Development in Cystic Fibrosis.
Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Inflammation; Losartan | 2020 |
Angiotensin II receptor type I-regulated anion secretion in cystic fibrosis pancreatic duct cells.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Angiotensin II; Angiotensin Receptor Antagonists; | 1997 |